Bis-cyclopropane analog of disorazole C1 is a microtubuledestabilizing agent active in ABCB1-overexpressing human colon cancer cells

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40866-40879

  Wu, Shaoyu ^a,b,c   Guo, Zhijian ^c   Hopkins, Chad D ^d   Wei, Ning ^a,b   Chu, Edward ^a,b   Wipf, Peter ^b,d   Schmitz, John C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Disorazole; Human colorectal cancer; Tubulin polymerization

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA TUBULIN; CELL PROTEIN; CYCLOPROPANE DERIVATIVE; DISORAZOLE C1; DOCETAXEL; MICROTUBULE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; ABCB1 PROTEIN, HUMAN; MACROLIDE; MULTIDRUG RESISTANCE PROTEIN; OXAZOLE DERIVATIVE; TUBULIN MODULATOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG STRUCTURE; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; METASTASIS; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN INTERACTION; SENESCENCE; CELL MOTION; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MICROTUBULE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MACROLIDES; MICROTUBULES; OXAZOLES; P-GLYCOPROTEINS; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 84950969741     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5885     Document Type: Article

References (43)

1. Altmann KH, and Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep. 2007; 24:327-57.
2. Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, and Desaubry LG. Cancer wars: natural products strike back. Front Chem. 2014; 2:20.
3. Cragg GM, Grothaus PG, and Newman DJ. New horizons for old drugs and drug leads. J Nat Prod. 2014; 77:703-23.
4. Cragg GM, and Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013; 1830:3670-95.
5. Lane AL, and Moore BS. A sea of biosynthesis: marine natural products meet the molecular age. Nat Prod Rep. 2011; 28:411-28.
6. Olano C, Mendez C, and Salas JA. Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis. Nat Prod Rep. 2009; 26:628-60.
7. Nandy JP, Prakesch M, Khadem S, Reddy PT, Sharma U, and Arya P. Advances in solution-and solid-phase synthesis toward the generation of natural product-like libraries. Chem Rev. 2009; 109:1999-2060.
8. Virshup AM, Contreras-Garcia J, Wipf P, Yang W, and Beratan DN. Stochastic voyages into uncharted chemical space produce a representative library of all possible druglike compounds. J Am Chem Soc. 2013; 135:7296-303.
9. Wipf P, Graham TH, and Xiao J. From natural products to biological tools. Pur Appl Chem. 2007; 79:753-61.
10. Watson NS, and Procopiou PA. Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. Prog Med Chem. 1996; 33:331-78.
11. Wipf P, and Halter RJ. Chemistry and biology of wortmannin. Org Biomol Chem. 2005; 3:2053-61.
12. Wipf P, Reeves JT, Balachandran R, and Day BW. Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. J Med Chem. 2002; 45:1901-17.
13. Hopkins CD, and Wipf P. Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides. Nat Prod Rep. 2009; 26:585-601.
14. Irschik H, Jansen R, Gerth K, Hofle G, and Reichenbach H. Disorazol A, an efficient inhibitor of eukaryotic organisms isolated from myxobacteria. J Antibiot (Tokyo). 1995; 48:31-5.
15. Jansen R, Irschik H, Reichenbach H, Wray V, and Hofle G. Disorazoles, highly cytotoxic metabolites from the sorangicin-producing bacterium Sorangium cellulosum, strain so ce12. Leibigs Ann Chem. 1994; 1994:759-73.
16. Wipf P, and Graham TH. Total synthesis of (-)-disorazole C1. J Am Chem Soc. 2004; 126:15346-7.
17. Lazo JS, Reese CE, Vogt A, Vollmer LL, Kitchens CA, Gunther E, Graham TH, Hopkins CD, and Wipf P. Identifying a resistance determinant for the antimitotic natural products disorazole C1 and A1. J Pharmacol Exp Ther. 2010; 332:906-11.
18. Tierno MB, Kitchens CA, Petrik B, Graham TH, Wipf P, Xu FL, Saunders WS, Raccor BS, Balachandran R, Day BW, Stout JR, Walczak CE, Ducruet AP, et al. Microtubule binding and disruption and induction of premature senescence by disorazole C. J Pharmacol Exp Ther. 2009; 328:715-22.
19. Wipf P, Graham TH, Vogt A, Sikorski RP, Ducruet AP, and Lazo JS. Cellular analysis of disorazole C and structureactivity relationship of analogs of the natural product. Chem Biol Drug Des. 2006; 67:66-73.
20. Xu FL, Rbaibi Y, Kiselyov K, Lazo JS, Wipf P, and Saunders WS. Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1. BMC Chem Biol. 2010; 10:1.
21. 2-disorazole C1. Org Lett. 2011; 13:4088-91.
22. Wang Z, and Silverman RB. Synthesis of cyclopropane isosteres of the antiepilepsy drug vigabatrin and evaluation of their inhibition of GABA aminotransferase. J Enzyme Inhib Med Chem. 2004; 19:293-301.
23. Yeo HL, Song YS, Ryu JH, and Kim HD. Design, synthesis, and biological evaluation of cyclopropyl analogues of stilbene with raloxifene side chain as subtype-selective ligands for estrogen receptor. Arch Pharm Res. 2013; 36:1096-103.
24. Blagosklonny MV, Robey R, Bates S, and Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest. 2000; 105:533-9.
25. Fan S, Cherney B, Reinhold W, Rucker K, and O'Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res. 1998; 4:1047-54.
26. Shen H, Lee FY, and Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011; 337:423-32.
27. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, and Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest. 1995; 95:2205-14.
28. Rothermel J, Wartmann M, Chen T, and Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol. 2003; 30:51-5.
29. Parker AL, Kavallaris M, and McCarroll JA. Microtubules and their role in cellular stress in cancer. Front Oncol. 2014; 4:153.
30. Hiser L, Aggarwal A, Young R, Frankfurter A, Spano A, Correia JJ, and Lobert S. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell Motil Cytoskeleton. 2006; 63:41-52.
31. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Cascon A, Robledo M, and Rodriguez-Antona C. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken). 2010; 67:214-23.
32. Komlodi-Pasztor E, Sackett D, Wilkerson J, and Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol. 2011; 8:244-50.
33. Alexandrova N, Niklinski J, Bliskovsky V, Otterson GA, Blake M, Kaye FJ, and Zajac-Kaye M. The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol. 1995; 15:5188-95.
34. Pasquier E, and Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life. 2008; 60:165-70.
35. Yue QX, Liu X, and Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med. 2010; 76:1037-43.
36. Katsetos CD, and Draber P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm Des. 2012; 18:2778-92.
37. Lee JJ, and Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res. 2008; 14:1618-24.
38. Bourgarel-Rey V, El Khyari S, Rimet O, Bordas B, Guigal N, Braguer D, Seree E, Barra Y, and Briand C. Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used. Eur J Cancer. 2000; 36:1043-9.
39. Preitner N, Quan J, Nowakowski DW, Hancock ML, Shi J, Tcherkezian J, Young-Pearse TL, and Flanagan JG. APC is an RNA-binding protein, and its interactome provides a link to neural development and microtubule assembly. Cell. 2014; 158:368-82.
40. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, and Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol. 2000; 2:709-17.
41. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U, and Fojo AT. Microtubule-targeting agents augment the toxicity of DNAdamaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci U S A. 2015; 112:1571-6.
42. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE, and Gazdar A. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res. 1987; 47:6710-8.
43. Korff T, and Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998; 143:1341-52.